· Pharma · Pharma Desk
Apotex's Apo-Semaglutide reaches Canadian pharmacies at roughly C$114 per four-week supply, reframing the access debate as U.S. patent cliffs and 505(j) pathways come into view.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.